Patents Assigned to Chugai Seiyaku Kabushiki Kaisha
  • Publication number: 20210107994
    Abstract: The present inventors examined the procoagulant activity of a multispecific antigen-binding molecule that functionally substitutes for FVIII using blood and plasma derived from FIX disorder patients. The result showed that multispecific antigen-binding molecules that functionally substitute for FVIII can be used not only as methods for preventing and/or treating bleeding in hemophilia A, acquired hemophilia A, von Willebrand disease, and hemophilia C, which are caused by FVIII dysfunction, but also as methods for preventing and/or treating bleeding in FIX disorders, because of their procoagulant activity. Furthermore, the effect of a FIX formulation could be enhanced by using it in combination with a multispecific antigen-binding molecule that functionally substitutes for FVIII, and it was shown that the combined use is promising as a combination therapy that shows stable hemostatic effects.
    Type: Application
    Filed: March 30, 2018
    Publication date: April 15, 2021
    Applicants: PUBLIC UNIVERSITY CORPORATION NARA MEDICAL UNIVERSITY, CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Midori Shima, Keiji Nogami, Kenichi Ogiwara
  • Publication number: 20210107995
    Abstract: The present inventors produced a variety of bispecific antibodies that specifically bind to both F. IX/F. IXa and F. X, and functionally substitute for F. VIIIa, i.e., have a cofactor function to promote F. X activation via F. IXa. Among these antibodies, the antibody A44/B26 reduced coagulation time by 50 seconds or more as compared to that observed when the antibody was not added. The present inventors produced a commonly shared L chain antibody from this antibody using L chains of A44, and showed that A44L can be used as commonly shared L chains, although the activity of the resulting antibody is reduced compared to the original antibody (A44HL-B26HL). Further, with appropriate CDR shuffling, the present inventors successfully produced highly active multispecific antibodies that functionally substitute for coagulation factor VIII.
    Type: Application
    Filed: December 22, 2020
    Publication date: April 15, 2021
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Kunihiro Hattori, Tetsuo Kojima, Hiroyuki Saito, Taro Miyazaki, Tetsuhiro Soeda
  • Patent number: 10961530
    Abstract: An objective of the present invention is to provide target tissue-specific antigen-binding molecules, antigen-binding molecules whose antigen-binding activity varies depending on the concentration of an unnatural compound, libraries comprising a plurality of the antigen-binding molecules which are different from one another, pharmaceutical compositions comprising the antigen-binding molecules, methods of screening for the antigen-binding molecules, and methods for producing the antigen-binding molecules. The present inventors created antigen-binding domains whose antigen-binding activity varies depending on the concentration of a small molecule compound or antigen-binding molecules containing an antigen-binding domain, and libraries comprising a plurality of the antigen-binding domains which are different from one another or antigen-binding domains, and demonstrated that the above-noted objective could be achieved by using the libraries.
    Type: Grant
    Filed: December 4, 2014
    Date of Patent: March 30, 2021
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Shigero Tamba, Shun Shimizu, Kanako Tatsumi, Shojiro Kadono, Hiroki Kawauchi, Kazuhiro Ohara, Masayuki Matsushita, Takashi Emura, Masaki Kamimura
  • Publication number: 20210087572
    Abstract: The present invention provides modified aminoacyl-tRNA synthetases (ARSs) having increased reactivity with N-methyl amino acids compared to natural aminoacyl-tRNA synthetases. The modified aminoacyl-tRNA synthetases according to the present invention can aminoacylate tRNAs with their corresponding N-methyl-substituted amino acids such as N-methyl-phenylalanine, N-methyl-valine, N-methyl-serine, N-methyl-threonine, N-methyl-tryptophan and N-methyl-leucine more efficiently than natural aminoacyl-tRNA synthetases. The present invention enables a more efficient production of polypeptides containing N-methyl amino acids.
    Type: Application
    Filed: September 18, 2020
    Publication date: March 25, 2021
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Atsushi OHTA, Yusuke YAMAGISHI, Atsushi MATSUO
  • Publication number: 20210079378
    Abstract: The present inventors discovered that antibodies having weaker antigen-binding activity at the early endosomal pH in comparison with that at the pH of plasma are capable of binding to multiple antigen molecules with a single antibody molecule, have long half-lives in plasma, and have improved durations of time in which they can bind to antigen.
    Type: Application
    Filed: September 14, 2020
    Publication date: March 18, 2021
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki IGAWA, Shinya ISHII, Atsuhiko MAEDA, Takashi NAKAI
  • Publication number: 20210079379
    Abstract: The present inventors discovered that antibodies having weaker antigen-binding activity at the early endosomal pH in comparison with that at the pH of plasma are capable of binding to multiple antigen molecules with a single antibody molecule, have long half-lives in plasma, and have improved durations of time in which they can bind to antigen.
    Type: Application
    Filed: September 14, 2020
    Publication date: March 18, 2021
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki IGAWA, Shinya ISHII, Atsuhiko MAEDA, Takashi NAKAI
  • Publication number: 20210061860
    Abstract: An object of the present invention is to provide methods of discovering drugs effective for tough targets, which have conventionally been discovered only with difficulty. The present invention relates to novel methods for cyclizing peptide compounds, and novel peptide compounds and libraries comprising the same, to achieve the above object.
    Type: Application
    Filed: September 3, 2020
    Publication date: March 4, 2021
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Shiori KARIYUKI, Takeo Ilda, Miki Kojima, Ryuichi Takeyama, Mikimasa Tanada, Tetsuo Kojima, Hitoshi Ilkura, Atsushi Matsuo, Takuya Shiraishi, Takashi Emura, Kazuhiko Nakano, Koji Takano, Kousuke Asou, Takuya Torizawa, Ryusuke Takano, Nozomi Hisada, Naoaki Murao, Atsushi Ohta, Kaori Kimura, Yusuke Yamagishi, Tatsuya Kato
  • Patent number: 10934351
    Abstract: An objective of the present invention is to obtain two types of substantively homogeneous cancer stem cell populations which can be characterized using the cell surface marker Lgr5, and to provide cancer therapeutics using an antibody against a cell membrane molecule specifically expressed in these cancer stem cells by identifying said cell membrane molecule. A further objective is to provide, using an antibody against a cell membrane molecule specifically expressed in cancer stem cells, a reagent for detecting cancer stem cells, and a method for diagnosing and sorting cancer patients. The present inventors discovered that highly pure large intestine cancer stem cells (CSC) can be obtained in a large quantity, and identified the two types of conditions of large intestine CSCs distinguishable through Lgr5 expression. Moreover, the present inventors discovered that an antibody against a cell membrane molecule specifically expressed in said cancer stem cells can damage said cells.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: March 2, 2021
    Assignee: CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Tatsumi Yamazaki, Hisafumi Okabe, Shinta Kobayashi, Takeshi Watanabe, Koichi Matsubara, Osamu Natori, Atsuhiko Kato, Masami Suzuki
  • Patent number: 10934344
    Abstract: The present inventors devised methods for efficiently purifying bispecific antibodies using a chromatography column based on the difference in isoelectric points between the H chains of two types of antibodies, wherein the difference is introduced by modifying the amino acids present on the surface of the antibody variable regions of two types of antibodies that constitute a bispecific antibody. Furthermore, the inventors devised methods for efficiently purifying bispecific antibodies using a chromatography column by linking respective antigen binding sites (heavy chain variable regions) to the antibody constant regions having different isoelectric points, and then coexpressing these antibodies.
    Type: Grant
    Filed: April 19, 2017
    Date of Patent: March 2, 2021
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Tomoyuki Igawa, Hiroyuki Tsunoda
  • Publication number: 20210052550
    Abstract: A composition which comprises substance represented by Formula (I), [Meanings of the symbols that are included in the formula are given in the specification as definitions] a pharmaceutically acceptable carrier, and a dissolution aid.is useful for improving solubility, oral absorbability and/or absorbability in blood of a poorly water-soluble or water insoluble tetracyclic compounds having an ALK inhibitory activity that are useful as a prophylactic and/or therapeutic agent for cancer, depression, and cognitive function disorder.
    Type: Application
    Filed: April 7, 2020
    Publication date: February 25, 2021
    Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Kentaro FURUMOTO, Koji SHIRAKI, Tomoaki HIRAYAMA
  • Patent number: 10919953
    Abstract: An objective of the present invention is to provide an Fc region variant with enhanced Fc?RIIb-binding activity, and/or enhanced binding selectivity to Fc?RIIb compared to Fc?RIIa (type R), as compared to those of a polypeptide containing an Fe region to which an amino acid alteration(s) has not been introduced; a polypeptide which includes the Fc region variant; a pharmaceutical composition containing the polypeptide; preventing therapeutic or preventive agent for immunological inflammatory diseases that includes the pharmaceutical composition; a production method thereof; and a method of enhancing Fc?RIIb-binding activity and also enhancing binding selectivity to Fc?RIIb compared to Fc?RIIa (type R).
    Type: Grant
    Filed: August 23, 2013
    Date of Patent: February 16, 2021
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Hitoshi Katada, Shojiro Kadono, Futa Mimoto, Tomoyuki Igawa
  • Publication number: 20210040147
    Abstract: The present invention provides efficient methods based on alteration of the protein A-binding ability, for producing or purifying multispecific antibodies having the activity of binding to two or more types of antigens to high purity through a protein A-based purification step alone. The methods of the present invention for producing or purifying multispecific antibodies which feature altering amino acid residues of antibody heavy chain constant region and/or variable region. Multispecific antibodies with an altered protein A-binding ability, which exhibit plasma retention comparable or longer than that of human IgG1, can be efficiently prepared in high purity by introducing amino acid alterations of the present invention into antibodies.
    Type: Application
    Filed: October 22, 2020
    Publication date: February 11, 2021
    Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Tomoyuki Igawa, Zenjiro Sampei, Tetsuya Wakabayashi, Eriko Ito
  • Publication number: 20210024524
    Abstract: The present invention provides compounds represented by formula (1) below and pharmacologically acceptable salts thereof: wherein R1, R2, R3, and R4 are as defined in the claims.
    Type: Application
    Filed: February 28, 2020
    Publication date: January 28, 2021
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Yoshikazu Nishimura, Toru Esaki, Tatsuya Tamura
  • Patent number: 10898572
    Abstract: Addition of argininamide or valinamide to a highly concentrated antibody solution was found to lead to remarkable stabilization, in particular, stabilization against photostress.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: January 26, 2021
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Daisuke Kameoka, Masaya Yasutake
  • Publication number: 20210017286
    Abstract: The present invention provides a pharmaceutical composition for treating IL-6-related diseases containing an IL-6 inhibitor as an active ingredient, wherein the pharmaceutical composition is routinely administered after a short-interval dosing period where the same dose as the routine dose is administered at a shorter interval than the routine dosing interval.
    Type: Application
    Filed: August 3, 2020
    Publication date: January 21, 2021
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Takahiro Kakehi, Akinori Yamada, Yoshimasa Ishida
  • Publication number: 20210017256
    Abstract: The disclosure provides anti-DENV antibodies having a cross-reactivity to ZIKV and methods of making and using the same. The anti-DENV antibodies have uses that include treating or preventing ZIKV infection.
    Type: Application
    Filed: March 15, 2019
    Publication date: January 21, 2021
    Applicants: Chugai Seiyaku Kabushiki Kaisha, Agency for Science, Technology & Research
    Inventors: Katja FINK, Cheng-I WANG, Lisa Fong Poh NG, Laurent RENIA, Zenjiro SAMPEI, Xing'er Christine XOO
  • Publication number: 20210017176
    Abstract: The present invention provides the compound, 3-[(1S,2S)-1-[5-[(4S)-2,2-Dimethyloxan-4-yl]-2-(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-1-yl]-2-methylcyclopropyl]-4H-1,2,4-oxadiazol-5-one, or a pharmaceutically acceptable salt of the compound, as well as a preventative agent or a therapeutic agent for non-insulin-dependent diabetes mellitus (Type 2 diabetes) or obesity containing such compound.
    Type: Application
    Filed: October 7, 2020
    Publication date: January 21, 2021
    Applicant: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Hitoshi YOSHINO, Satoshi TSUCHIYA, Atsushi MATSUO, Tsutomu SATO, Masahiro NISHIMOTO, Kyoko OGURI, Hiroko OGAWA, Yoshikazu NISHIMURA, Yoshiyuki FURUTA, Hirotaka KASHIWAGI, Nobuyuki HORI, Takuma KAMON, Takuya SHIRAISHI, Shoshin YOSHIDA, Takahiro KAWAI, Satoshi TANIDA, Masahide AOKI
  • Publication number: 20200407463
    Abstract: The inventors discovered that by administering a pharmaceutical composition comprising a bispecific antigen-binding molecule that recognizes blood coagulation factor IX and/or activated blood coagulation factor IX and blood coagulation factor X and/or activated blood coagulation factor X according to a given dosage regimen, diseases that develop and/or progress due to a decrease or deficiency in the activity of blood coagulation factor VIII and/or activated blood coagulation factor VIII can be prevented and/or treated more effectively.
    Type: Application
    Filed: September 11, 2020
    Publication date: December 31, 2020
    Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventor: Koichiro Yoneyama
  • Patent number: 10874677
    Abstract: The present application discloses methods for treating an IL-6-mediated disorder such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic JIA (sJIA), polyarticular course JIA (pcJIA), systemic sclerosis, or giant cell arteritis (GCA), with subcutaneously administered antibody that binds interleukin-6 receptor (anti-IL-6R antibody). In particular, it relates to identification of a fixed dose of anti-IL-6R antibody, e.g. tocilizumab, which is safe and effective for subcutaneous administration in patients with IL-6-mediated disorders. In addition, formulations and devices useful for subcutaneous administration of an anti-IL-6R antibody are disclosed.
    Type: Grant
    Filed: January 22, 2019
    Date of Patent: December 29, 2020
    Assignees: Hoffmann-La Roche Inc., CHUGAI SEIYAKU KABUSHIKI KAISHA
    Inventors: Xiaoping Zhang, Kimio Terao
  • Publication number: 20200397794
    Abstract: The present invention relates to a pharmaceutical composition comprising poorly soluble compounds such as BSC class II or IV kinase inhibitors, a process for the preparation thereof and its use in the treatment of diseases, in particular cancer, further particularly in non-small lung cancer.
    Type: Application
    Filed: January 27, 2020
    Publication date: December 24, 2020
    Applicants: Hoffmann-La Roche Inc., Chugai Seiyaku Kabushiki Kaisha
    Inventors: Susanne Meier, Carsten Bruesewitz